QUILLIVANT XR
Peakmethylphenidate hydrochloride
NDAORALFOR SUSPENSION, EXTENDED RELEASE
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
12
Clinical Trials (5)
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
Started Sep 2014
36 enrolled
ADHDAutism
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Started Apr 2011
299 enrolled
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Started Nov 2010
725 enrolled
Attention Deficit/Hyperactivity Disorder
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Started Jul 2009
357 enrolled
Attention Deficit Disorder With Hyperactivity
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Started Apr 2009
45 enrolled
Attention Deficit Hyperactivity Disorder
Loss of Exclusivity
LOE Date
Feb 15, 2031
60 months away
Patent Expiry
Feb 15, 2031